Shuai Wang

Organic Chemistry

Associate Professor

shuaiwang@fudan.edu.cn

Fudan University-DSM Joint Laboratory

86-13526656062

Research Interests

  • Development of innovative antiviral drugs based on computer aided and drug mechanism of action

  • Development of innovative anti-tumor drugs based on computer aided and drug action mechanism

  • Construction of diverse compound library and new drug screening platform

Academic Appointments

  • Secretary of Chinese Pharmaceutical Chemistry Committee

  • Young Editorial Member of Acta. Pharm Sin B (APSB)

Prizes and awards

  • 2023 Shanghai Magnolia Talent Plan Pujiang project

Biography

  • 2010.9-2014.7BSc, School of Pharmacy, Jinzhou Medical University

  • 2014.9-2017.7Master, School of Pharmacy, Zhengzhou University

  • 2017.9-2021.7PhD, Institute of Materia Medica, Zhengzhou University

  • 2019.9-2021.2Visiting scholar, Gordon Center for Medical Imaging, Harvard Medical School

  • 2021.7-2022.7Research Assistant, Department of Chemistry, Fudan University

  • 2022.7- Associate Professor, Department of Chemistry, Fudan University

  • 2023.10-           Secretary of Chinese Pharmaceutical Chemistry Committee, Chinese Pharmaceutical society

Teaching

  • Advance in pharmaceutical chemistry

  • Pharmaceutical synthetic chemistry

Key Publications

  1. Wang, J. S., Zhao, K. X., Zhang K., Pannecouque, C.; Clercq, E.; Wang, S.*; Chen, F. E.*, Structure-guided design of novel biphenyl-quinazoline derivatives as potent non-nucleoside reverse transcriptase inhibitors featuring improved anti-resistance, selectivity, and solubility, Bioorg. Chem.2024, 147, 107340.

  2. Sang, Y. L.; Pannecouque, C.; Clercq, E.; Wang, S.*; Chen, F. E.*, Fragment hopping-based design of novel biphenyl-DAPY derivatives as potent NNRTIs featuring significantly improved anti-resistance efficacy. J. Med. Chem., 2023, 66, 4755-4767.   

  3. Sang, Y. L.; Pannecouque, C.; Clercq, E.; Wang, S.*; Chen, F. E.*, Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability. Acta. Pharm Sin B, 2023, 13, 3054-3066.

  4. Zhao, L. M.; Pannecouque, C.; Clercq, E.; Wang, S.; Chen, F. E. Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility. Acta Pharm Sin B2023, 13, 4906-4917.    

  5. Zhou, R. L.; Ju, Z.; Pannecouque, C.; Clercq, E.; Wang, S.*; Chen, F. E.*, Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs. Eur. J. Med. Chem.2023, 246, 114939.

  6. Ling, X.; Hao, Q. Q.; Huang, W. J.; Pannecouque, C.; De Clercq, E.; Wang, S.*; Chen, F. E.*, Development of novel S-N3-DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity. Eur. J. Med. Chem.2023, 247, 115042.

  7. Zhao, L. M.; Pannecouque, C.; De Clercq, E.; Wang, S.*; Chen, F. E.*, Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety. Chin. Chem. Lett.2023, 108261.

  8. Hao, Q. Q.; Chen, X. M.; Pannecouque, C.; De Clercq, E.; Wang, S.*; Chen, F. E.*, Structure-directed linker optimization of novel HEPTs as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Chem.2023, 133, 106413.

  9. Wang, S.; Chen, F. E.*, Small-molecule MDM2 inhibitors in clinical trials for cancer therapy. Eur. J. Med. Chem. 2022, 236, 114334.

  10. Wang, S.1; Wang, S. Q.1; Teng, Q. X.; Lei, Z. N.; Chen, Z. S.; Chen, X. B.*; Liu, H. M.*; Yu, B.*, Discovery of the triazolo[1,5-a]pyrimidine-based derivative WS-898 as a highly efficacious and orally bioavailable ABCB1 inhibitor capable of overcoming multidrug resistance. J. Med. Chem.2021, 64 (21), 16187-16204.

  11. Wang, S.; Yuan, X. H.; Wang, S. Q.; Zhao, W.; Chen, X. B.; Yu, B.*, FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. Eur. J. Med. Chem.2021, 214, 113218.

  12. Wang, S.1; Shen, D. D.1; Zhao, L. J.1; Yuan, X. H.; Cheng, J. L.; Yu, B.*; Zheng, Y. C.*; Liu, H. M.*, Discovery of [1,2,4]triazolo[1,5-a]pyrimidine derivatives as new bromodomain-containing protein 4 (BRD4) inhibitors. Chin. Chem. Lett. 2020, 31 (2), 418-422.

  13. Wang, S.1; Wang, S. Q.1; Teng, Q. X.1; Yang, L. L.; Lei, Z. N.; Yuan, X. H.; Huo, J. F.; Chen, X. B.; Wang, M. R.; Yu, B.*; Chen, Z. S.*; Liu, H. M.*, Structure-based design, synthesis, and biological evaluation of new triazolo[1,5-a]pyrimidine derivatives as highly potent and orally active ABCB1 modulators. J. Med. Chem.2020, 63 (24), 15979-15996.

  14. Wang, S.1; Ma, X. B.1; Yuan, X. H.; Yu, B.*; Xu, Y. C.*; Liu, H. M.*, Discovery of new [1,2,4] triazolo[1,5-a]pyrimidine derivatives that Kill gastric cancer cells via the mitochondria pathway. Eur. J. Med. Chem. 2020, 203, 112630.

  15. Wang, S.1; Zhao, L. J.1; Shi, X. J.1; Ding, L. N.1; Yang, L. L.; Wang, Z. Z.; Shen, D. D.; Tang, K.; Li, X. J.; Mamun, M.; Li, H. J.; Yu, B.*; Zheng, Y. C.*; Wang, S. M.*; Liu, H. M.*, Development of highly potent, selective, and cellular active triazolo[1,5-a]pyrimidine-based inhibitors targeting the DCN1-UBC12 protein-protein interaction. J. Med. Chem.2019, 62 (5), 2772-2797.

  16. Wang, S.1; Li, Z. R.1; Suo, F. Z.; Yuan, X. H.; Yu, B.*; Liu, H. M.*, Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors. Eur. J. Med. Chem. 2019, 167, 388-401.

  17. Wang, S.1; Zhao, L. J.1; Zheng, Y. C.; Shen, D. D.; Miao, E. F.; Qiao, X. P.; Zhao, L. J.; Liu, Y.; Huang, R.; Yu, B.*; Liu, H. M.*, Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors. Eur. J. Med. Chem.2017, 125, 940-951.